---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-032077"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:41:44.412924+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track

## Summary
- Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.
- Cash and equivalents $109.4M at Dec 31, 2025; Feb 2026 offering raised ~$144M gross.
- R&D expenses $42.1M, up 73% YoY, driven by Phase 2 tibulizumab programs.
- Phase 2 TibuSHIELD (HS) topline data expected Q4 2026; TibuSURE (SSc) data H1 2027.
- Appointed Sandeep Kulkarni as CEO in Jan 2026; added two board members in Feb 2026.

## SEC filing metadata
- accession: 0001104659-26-032077
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/0001104659-26-032077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/tm269296d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-032077
- JSON: https://secwatch.observer/filing/0001104659-26-032077.json
- Plain text: https://secwatch.observer/filing/0001104659-26-032077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.